Efficacy of Upadacitinib and Dupilumab on Achieving Stringent and ...

New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority ...

Upadacitinib also showed superiority versus dupilumab for all ranked secondary endpoints, including the rapid onset of achieving near complete ...

Aggregate Response Benefit in Skin Clearance and Itch Reduction ...

2). A larger proportion of patients achieved incrementally greater skin clearance with upadacitinib than with dupilumab across all the EASI thresholds. The ...

Safety and efficacy of upadacitinib in combination with - BINASSS

A substantial proportion of patients achieved the stringent ... monoclonal antibody dupilumab achieve clear or almost clear skin ...

Efficacy and Safety of Upadacitinib in Patients With Moderate to ...

1-3 Additionally, the pro- portion of patients achieving clear or almost-clear skin with the injectable immunotherapy dupilumab after 16 weeks ...

Upadacitinib beats dupilumab in different body regions

The rates of participants achieving EASI 100, 90, and 75 in the head-and-neck region showed interesting results [2]. “What you can see is a very ...

Safety and efficacy of upadacitinib in combination with topical ...

For many patients with moderate-to-severe atopic dermatitis, systemic therapy in addition to topical corticosteroids is recommended to control symptoms. This ...

Dermatology and Therapy on X: "Efficacy of #Upadacitinib and ...

Efficacy of #Upadacitinib and #Dupilumab on Achieving Stringent and Composite Skin and Itch Outcomes: an Indirect Comparison of Adults with ...

New 'Level Up' Data on Upadacitinib (Rinvoq) for Atopic Dermatitis ...

Upadacitinib showed significant efficacy in patients with atopic dermatitis who did not respond to dupilumab, achieving EASI-75 in nearly 80% by ...

Recent updates on systemic treatment of atopic dermatitis

Similarly, 48% and 62% of the upadacitinib 15 mg and 30 mg groups, respectively, achieved a vIGA-AD score of 0 or 1 versus 8% of the placebo ...

Upadacitinib Shows Superiority to Dupilumab for Atopic Dermatitis ...

When initiated at a 15 mg dose and escalated to 30 mg, upadacitinib showed superiority compared with dupilumab, achieving Eczema Area and ...

Upadacitinib Effective and Safe in Atopic Dermatitis at 52 Weeks

At 52 weeks, 50.8% of those in the upadacitinib 15 mg plus topical corticosteroids group achieved the endpoint — an improvement in EASI score of ...

Upadacitinib in the Treatment of Atopic Dermatitis: A Systematic ...

For efficacy, the overall pooled proportions of AD patients achieving EASI 50, EASI 75, EASI 90, and EASI 100 after upadacitinib therapy ...

Upadacitinib in adults with moderate to severe atopic dermatitis

The mean (SE) primary efficacy end point was 39% (6.2%), 62% (6.1%), and 74% (6.1%) for the upadacitinib 7.5-, 15-, and 30-mg groups, ...

Real-life management of atopic dermatitis patients with an ...

Forty-eight patients were included (30 men): 42 patients had shown a PR (87.5%) and 6 had shown NR (12.5%) after 3 months of dupilumab 300mg/2 ...

JAK Inhibitor Updates: Upadacitinib and the Level-Up Trial - HCPLive

HCPLive: The Level-Up trial showed promising phase 3b/4 data comparing the JAK-1 inhibitor upadacitinib to the IL-4/13 inhibitor dupilumab.

Exposure‐Response Analyses for Upadacitinib Efficacy in Subjects ...

Recently, dupilumab, a monoclonal antibody that inhibits interleukin (IL)-4 and IL-13 signaling, has been approved by the Food and Drug ...

Efficacy and Safety of Upadacitinib Versus Dupilumab Treatment for ...

Conclusion: Compared to dupilumab, upadacitinib treatment provided higher rates of rapid, sustained efficacy for the head and neck, trunk, upper ...

Upadacitinib in adults with moderate to severe atopic dermatitis

9 Dupilumab administered every other week provided significant benefit compared with placebo in phase 2 and 3 trials by week 16; how- ever, less ...

Abstract N - Amazon S3

Here, we evaluated the efficacy of abrocitinib 100 mg compared with dupilumab or placebo in achieving stringent outcomes in JADE COMPARE ...

Atopic Dermatitis: Upadacitinib Superior to Dupilumab in Improving ...

Upadacitinib has a favorable aggregate response benefit compared with dupilumab and placebo for skin clearance and itch reduction among patients with moderate ...